



## Q3 Report – 2022/2023

1 November 2022 – 31 January 2023

### A word from the CEO – Karin Bryder

“Winter is coming”- well not really here in Lund. As the grey weather persists it is a pleasure to have such an interesting company and product to work with. This was the start I had prepared when writing the report in February. Now it is almost April – so let’s hope for spring and a warm Easter holiday. The WOUNDCOM project has had a busy time with process validation, production for the clinical investigation and establishing shelf life covering the clinical investigation (and more). A discussion with the EIC Fund regarding conversion of the convertible loan and with the European Innovation Council (EIC) regarding prolongation of the project is well on its way.

Are you a shareholder in CBC Derma Technologies AB, CBC Derma Technologies II AB or CBC Derma Technologies III AB? Then please read the note on page 4.

### Financial Report 1 November 2022 – 31 January 2023

Colzyx is an R&D company that has not yet generated any revenue from product sales.

SEK thousands [kSEK]	2022 Q3	2021 Q3	2022 Q1-Q3	2021 Q1-Q3
Revenues – <i>Grants &amp; other income</i>	2,093	1,167	2,206	5,356
<i>Capitalized work for own account</i>	630	1,063	4,120	2,218
Operating costs	-3,636	-3,330	-9,939	-10,312
Operating profit (EBIT)	-913	-1,101	-3,613	-2,738
Cash and cash equivalents (31 Jan)	21,316	36,441	21,316	36,441
Earnings per share [SEK]	-7.09	-8.58	-28.13	-21.33

### Financing

Colzyx and the EIC Fund are discussing a postponement until 31 July 2023 for the mandatory conversion of the convertible loan of EUR 1 million.

### Board of Directors

The current board of directors consists of Jens Hansson (chairman), Eskil Söderlind, Ingrid Atteryd Heiman, Göran Conradson and Ann-Christin Malmborg Hager. Presentations of the directors can be found on [www.colzyx.com](http://www.colzyx.com).

### Organization

Colzyx works with a virtual business model where C-level positions are employed, engaging specialized consultants and CROs for every development step. Currently Colzyx has three employees covering design and development, quality and regulatory and scientific/technical expertise, and management.

## Development progress

### Production of WOUNDCOM

Validation of large-scale production of WOUNDCOM is well on its way and we are looking forward to receiving products ready for clinical investigation. We have established a shelf life of 24 months so far, where WOUNDCOM shows no signs of deterioration. We anticipate having the same shelf-life as the matrix which is established as five years. The production is performed with an undisclosed strategic partner in Europe, working under GMP regulations.

### Clinical Trial

The submission to the German Ethics Committee was regrettably delayed due to high pressure on the health systems with Covid-19, influenza and RSV coemerging this autumn/winter. We submitted an application for the upcoming clinical investigation to the German Ethics Committee in the beginning of March 2023 and is awaiting its response. Colzyx is working with the German CRO Eurofins, Bioskin which is specialized in dermatological studies. We will conduct the study at 7-9 wound specialist clinics in Germany focusing on hard-to-heal leg ulcers.

### Veterinarian Market Possibilities

We are analyzing the possibility of letting veterinarians use WOUNDCOM for the animal care market. Case studies on inflicted traumatic wounds have been performed with positive feedback on several species. In February 2023 WOUNDCOM was represented by board member Göran Conradson at the Gothenburg Horse show. Discussions and insights from this venue encourage us to reach out for further contacts and activities. Faster healing and minimizing the use of antibiotics and anti-inflammatory drugs is beneficial both for the animal and its owner.

### Presentations and Publications

As an invited speaker Dr. Mörgelin presented the WOUNDCOM project at the Advanced Wound Care Summit (Europe) in Berlin 14 December 2022. The meeting focused on industry-led development of innovative wound care treatments.

## Intellectual Property

Colzyx owns three patent families with the aim to cover all use of the active peptides discovered by Mörgelin - Abdillahi. The establishment of the patent portfolio is progressing as planned. The latest news is that the first application covering a set of peptides including the two used in WOUNDCOM has received a final grant in February. This means that Colzyx now has patent protection covering the peptides used in WOUNDCOM as well as a set of other peptides from Collagen VI with antimicrobial activity in the USA, China and Europe.

## COVID-19

COVID-19 has now entered as a recurrent respiratory virus in addition to the seasonal influenza and RSV. Outbursts of COVID-19 as well as other viral infections will still have some influence of timelines of tests performed and the clinical investigation but is believed to have a decreasing impact going forward.

--- oOo ---

Karin Bryder, CEO

[karin@colzyx.com](mailto:karin@colzyx.com)

+46 (0)70 683 4144



Colzyx started in 2016 acquiring discoveries and inventions made at the Medical Faculty at Lund University by Ass. Professor Matthias Mörglin and PhD student Suado Abdillahi. According to Swedish law, researchers at the university own their own inventions and thus any patent rights connected to them. However, all immaterial property rights were transferred to the company at its establishment. Thus, Colzyx holds all rights to current and future inventions.

### **The Discovery/Invention**

Mörgelin and Abdillahi discovered that a set of peptides from the alpha-3 chain from human collagen VI exhibits both unique wound healing properties as well as growth-inhibiting effects on "common" and multi-resistant bacteria. The alpha-3 chain has evolved during millions of years of evolution to promote wound healing and minimize bacterial infections, and it is these natural properties that form Colzyx technology platform and which Colzyx utilizes in its product development.



### **WOUNDCOM**

WOUNDCOM is Colzyx's first product based on two of the discovered bio-active peptides from the Collagen VI - alpha-3 chain that exhibits both wound healing and antibacterial effects. WOUNDCOM is composed of a bovine collagen I scaffold with the addition of synthetic peptides. WOUNDCOM will be regulated as a class III medical device according to the Medical Device Regulation (MDR, EU 2017/745). Biological, chemical, and clinical evidence will ensure that patients and medical professionals will benefit from a product that is proven safe and efficient. Upon finalizing all safety and efficacy data Colzyx will apply for market access in Europe (CE-mark) at a Notified Body (NB, acting as authority for medical devices). Currently NBs indicate a 24-month period as assessment time for a CE-approval. As part of the route to the CE-mark for WOUNDCOM, Colzyx already today works according to the requirements of a Quality Management System under MDR and ISO 13485.

### **Use**

WOUNDCOM is intended to manage injured skin by promoting wound healing and providing antimicrobial properties. The need for new forms of wound healing products is large in the areas of infection after surgery, infection of acute or burn wounds, venous chronic leg ulcers and in chronic wounds because of diabetes. WOUNDCOM has the potential to be used in all of these, as well as additional areas, where there is a pronounced need for better and faster wound healing and a simultaneous effect against bacterial infections.

### **OTHER OPPORTUNITIES based on COLZYX'S TECHNOLOGY PLATFORM**

Colzyx is focusing on the development and market approval of WOUNDCOM in Europe for treatment of injured skin. In addition, Colzyx is investigating the possibilities of COMBAT (peptides used as antibiotics), BIOCOM (peptides used in connection with implants) as well as other markets outside EU and additional treatment subjects for WOUNDCOM such as equestrian wound healing.

---

**IMPORTANT NOTE:****Are you a SHAREHOLDER in one of the CBC DERMA TECHNOLOGIES companies (SPVs)?**

Due to the turbulence created related to the recent bankruptcy of CBC Holding AB and CBC Investment Group AB, Colzyx would like to offer the shareholders of CBC Derma Technologies AB, CBC Derma Technologies II AB and CBC Derma Technologies III AB some further insight into the development of Colzyx AB.

If you are interested in receiving future quarterly reports, annual reports, press releases and other relevant information from Colzyx AB, write us an email to [info@colzyx.com](mailto:info@colzyx.com) and we will put you on our mailing list for future distributions of company information. Please state your name, phone number (voluntary) and which of the CBC Derma Technologies SPV(s) you have invested in.

GDPR note: By sending the described e-mail to [info@colzyx.com](mailto:info@colzyx.com) you consent to be registered on a mailing list that is kept digitally at Colzyx AB. Colzyx will not transfer the information to any third party and you can at any time request that Colzyx remove your information from the list.